Evidence map›Paper›PMID 36730773›Full record

ReviewCurrent opinion in ophthalmology2023

Detecting disease progression in mild, moderate and severe glaucoma.

Daniel L Liebman, Joanne C Wen, Lucy Q Shen

Abstract readReview
In one paragraph

Review in Current opinion in ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Daniel L LiebmanDepartment of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts.
Joanne C WenDepartment of Ophthalmology, Duke Eye Center, Durham, North Carolina.
Lucy Q ShenDepartment of Ophthalmology, Mass Eye and Ear, Boston, Massachusetts.
Massachusetts Eye and Ear Infirmary · USPartners In Health · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Innate and Adaptive Immunity in the Pathogenesis of GlaucomaR01EY031696 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Dong Feng Chen, Jianzhu Chen · 2021 to 2026
$5.2M
Development of a Next Generation Visual Performance Assessment System for RodentsR44EY025913 · NEI · AFASCI, INC. · PI CHEN, DONG FENG, LUO, GANG · 2019 to 2020
$1.5M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY031696NEI NIH HHS R44 EY025913
6 · The paper itself

Abstract

purpose of reviewThe purpose of this review is to examine contemporary techniques for detecting the progression of glaucoma. We provide a general overview of detection principles and review evidence-based diagnostic strategies and specific considerations for detecting glaucomatous progression in patients with mild, moderate and severe disease. RECENT

findingsDiagnostic techniques and technologies for glaucoma have dramatically evolved in recent years, affording clinicians an expansive toolkit with which to detect glaucoma progression. Each stage of glaucoma, however, presents unique diagnostic challenges. In mild disease, either structural or functional changes can develop first in disease progression. In moderate disease, structural or functional changes can occur either in tandem or in isolation. In severe disease, standard techniques may fail to detect further disease progression, but such detection can still be measured using other modalities. SUMMARY: Detecting disease progression is central to the management of glaucoma. Glaucomatous progression has both structural and functional elements, both of which must be carefully monitored at all disease stages to determine when interventions are warranted.

Indexed as

GlaucomaDisease ProgressionHumans

Identifiers

PMID36730773
PMCPMC12375374
OpenAlexW4318967640

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.